Zobrazeno 1 - 10
of 260
pro vyhledávání: '"Rachid Baz"'
Autor:
Hamza Hashmi, Doris K. Hansen, Lauren C. Peres, Omar Castaneda Puglianini, Ciara Freeman, Gabriel De Avila, Surbhi Sidana, Leyla Shune, Douglas W. Sborov, James Davis, Charlotte Wagner, Mehmet H. Kocoglu, Shebli Atrash, Peter Voorhees, Gary Simmons, Christopher Ferreri, Nilesh Kalariya, Larry D. Anderson Jr., Aimaz Afrough, Danai Dima, Jack Khouri, Joseph McGuirk, Fred Locke, Rachid Baz, Krina K. Patel, Melissa Alsina
Publikováno v:
Haematologica, Vol 109, Iss 5 (2023)
While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted chimeric antigen receptor (CAR) T-
Externí odkaz:
https://doaj.org/article/75a53724d8354ceda7fc08c876125b9e
Autor:
Krina Patel, Paula Rodríguez-Otero, Salomon Manier, Rachid Baz, Marc S. Raab, Michele Cavo, Natalie Callander, Luciano Costa, Philippe Moreau, Scott Solomon, Christine Chen, Noopur Raje, Christof Scheid, Michel Delforge, Jeremy Larsen, Thomas Pabst, Kenshi Suzuki, Anna Truppel-Hartmann, Zhihong Yang, Julia Piasecki, Jasper Felten, Andrea Caia, Mark Cook, Sergio Giralt, Maria-Victoria Mateos
Publikováno v:
HemaSphere, Vol 7, p e369897b (2023)
Externí odkaz:
https://doaj.org/article/4c0965e732c84effab073423b849e6b3
Autor:
Turab Mohammed, Moazzam Shahzad, Lauren Peres, Sushmita Khadka, Christelle Colinleitzinger, Abida Babu, William Doyle, Omar Castaneda Puglianini, Laura Oswald, Gabe De Avila, Ariel Grajales-Cruz, Brandon Blue, Jose Ochoa-Bayona, Eric Smith, Salvatore Corallo, Farhad Khimani, Rawan Faramand, Hany Elmariah, Aleksandr Lazaryan, Michael Jain, Hien Liu, Taiga Nishihori, Ken Shain, Rachid Baz, Melissa Alsina, Frederick Locke, Ciara Freeman, Doris Hansen
Publikováno v:
HemaSphere, Vol 7, p e46377e2 (2023)
Externí odkaz:
https://doaj.org/article/3816dc577cf240bcafe0c8f4c6641fec
Autor:
Cesar Rodriguez Valdes, Katja Weisel, Rachid Baz, Akshanth Polepally, Jeremy A. Ross, Ziyi Jin, Kristin D’amico, Orlando F. Bueno, Leanne Lash Fleming, Peter Voorhees
Publikováno v:
HemaSphere, Vol 7, p e60985f9 (2023)
Externí odkaz:
https://doaj.org/article/3928bd6ae4434486bf6eaef2cf4593fb
Autor:
Salomon Manier, Paula Rodríguez-Otero, Maria-Victoria Mateos, Hermann Einsele, Nizar J Bahlis, Nikhil Munshi, Sikander Ailawadhi, Bertrand Arnulf, Ajay Nooka, Ravi Vij, Ingerid Weum Abrahamsen, Annemiek Broijl, Sundar Jagannath, Reuben Benjamin, Usama Gergis, Douglas W. Sborov, Shinsuke Iida, Anna Truppel-Hartmann, Zhihong Yang, Julia Piasecki, Jasper Felten, Andrea Caia, Mark Cook, Rachid Baz
Publikováno v:
HemaSphere, Vol 7, p e3385948 (2023)
Externí odkaz:
https://doaj.org/article/5953e70c506043f1be82ad51da50daef
Autor:
Rachid Baz MD, Roy Furman MD, PhD, Katherine Simondsen PharmD, BCOP, Christine Stone PhD, MBA
Publikováno v:
Cancer Control, Vol 27 (2020)
Patients with multiple myeloma are at elevated risk of venous thromboembolism (VTE), the second leading cause of death in patients with cancer, but physician adherence to VTE prevention guidelines is low. Several organizations partnered in designing
Externí odkaz:
https://doaj.org/article/a3b5cddfc57340ea8145a5533abdc85c
Autor:
Praneeth Sudalagunta, Maria C. Silva, Rafael R. Canevarolo, Raghunandan Reddy Alugubelli, Gabriel DeAvila, Alexandre Tungesvik, Lia Perez, Robert Gatenby, Robert Gillies, Rachid Baz, Mark B. Meads, Kenneth H. Shain, Ariosto S. Silva
Publikováno v:
EBioMedicine, Vol 54, Iss , Pp - (2020)
Background: Multiagent therapies, due to their ability to delay or overcome resistance, are a hallmark of treatment in multiple myeloma (MM). The growing number of therapeutic options in MM requires high-throughput combination screening tools to bett
Externí odkaz:
https://doaj.org/article/2bfb0dce927d404ba1fd3ed314b63a77
Autor:
Joel G. Turner, Jana L. Dawson, Steven Grant, Kenneth H. Shain, William S. Dalton, Yun Dai, Mark Meads, Rachid Baz, Michael Kauffman, Sharon Shacham, Daniel M. Sullivan
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-11 (2016)
Abstract Background Acquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM). Despite recent advanced treatment options such as liposomal formulations, proteasome inhibitors, immunomodulatory drugs, myelo
Externí odkaz:
https://doaj.org/article/da979cebd0d7423693b42b5ba914e215
Publikováno v:
Advances in Hematology, Vol 2010 (2010)
Multiple myeloma is an incurable disease, although patient survival has increased with the availability of novel agents. Both multiple myeloma and its therapies often affect the renal, immune, skeletal, hematologic, and nervous systems. The resulting
Externí odkaz:
https://doaj.org/article/079c15e81cfa4218a90b17f08566fb79
Autor:
Doris K. Hansen, Surbhi Sidana, Lauren C. Peres, Christelle Colin Leitzinger, Leyla Shune, Alexandria Shrewsbury, Rebecca Gonzalez, Douglas W. Sborov, Charlotte Wagner, Danai Dima, Hamza Hashmi, Mehmet H. Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher Ferreri, Aimaz Afrough, Ankit Kansagra, Peter Voorhees, Rachid Baz, Jack Khouri, Melissa Alsina, Joseph McGuirk, Frederick L. Locke, Krina K. Patel
Publikováno v:
Journal of Clinical Oncology. 41:2087-2097
PURPOSE Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen–directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the phase II pivotal KarMMa trial, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09366877649aa67af7897535ea0e345d
https://doi.org/10.1200/jco.22.01365
https://doi.org/10.1200/jco.22.01365